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Abstract
Background: Patients with IBD and chronic inflammation refractory to conventional therapy often demonstrate higher 
risk of serious complications. Combinations of immunosuppression and biological treatment as well as surgical 
intervention are often used in this patient group. Hence, there is need for additional treatment options. In this 
observational study, focused on re-treatment and long-term results, Granulocyte/Monocyte Adsorption (GMA, 
Adacolumn®) treatment has been investigated to study efficacy, safety and quality of life in IBD-patients with chronic 
activity.
Methods: Fifteen patients with ulcerative colitis and 25 patients with Crohn's disease, both groups with chronically 
active inflammation refractory to conventional medication were included in this observational study. The patients 
received 5-10 GMA sessions, and the clinical activity was assessed at baseline, after each completed course, and at 
week 10 and 20 by disease activity index, endoscopy and quality of life evaluation. Relapsed patients were re-treated by 
GMA in this follow-up study up to 58 months.
Results: Clinical response was seen in 85% and complete remission in 65% of the patients. Ten patients in the UC-
group (66%) and 16 patients in the CD-group (64%) maintained clinical and endoscopic remission for an average of 14 
months. Fourteen patients who relapsed after showing initial remission were re-treated with GMA and 13 (93%) went 
into a second remission. Following further relapses, all of seven patients were successfully re-treated for the third time, 
all of three patients for the fourth time and one for a fifth time.
Conclusions: IBD-patients with chronic inflammation despite conventional therapy seem to benefit from GMA. Re-
treatment of relapsing remission patients seems to be effective.
Background
Inflammatory bowel diseases (IBD), divided into the two
main entities ulcerative colitis (UC) and Crohn's disease
(CD), is a debilitating chronic inflammation of the intes-
tine. A broad range of pharmacological therapies is avail-
able for treating IBD, including 5-aminosalicylate
preparations, corticosteroids, and immunosuppressants
(azathioprine/6-mercaptopurine). However, these treat-
ments are hampered by lack of response in some patients
and side effects may add to the disease complications
[1,2]. Furthermore, in recent years, monoclonal antibod-
ies to TNF-α (Tumor Necrosis Factor) have been
approved for both CD [3,4], including maintenance [5],
and UC [6-8], in patients who are unresponsive to the
aforementioned baseline conventional medications.
These biologics are associated with side effects such as
opportunistic infections, tuberculosis, demyelinating
syndromes, lymphoma and rarely also mortality [9-11]. In
addition all immunosuppressive therapies, especially
when used in combination, are associated with increased
risk of opportunistic infections [12]. Another option for
drug-refractory patients is surgery, an intervention asso-
ciated with increased morbidity and disability [13,14].
The treatment-related complications tend to have sub-
stantial impact on patients health-related quality of life
(HRQoL) [15-17]. In addition, according to a newly pub-
lished report from the IBSEN study, the subgroups of
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patients who display chronic inflammation despite treat-
ment reach 6% of UC- [18], and 19% of the CD-patients
[19]. Another important health-related quality of life
aspect concerns disease activity. Lix and co-authors
recently showed that one-third of the participants with
perpetual inflammation demonstrate significantly lower
improvement in disease-specific QoL compared to
patients with fluctuating activity [20]. Hence, there is a
need for effective and well-tolerated therapies for IBD-
patients with chronic inflammation who are unrespon-
sive or intolerant to first-line medications and biologics.
IBD-patients are characterised by elevated levels of
granulocytes and monocytes in peripheral blood, circu-
lating immune complexes, and leukocyte-derived inflam-
matory factors like cytokines and chemokines [21-24]. A
major mechanism behind IBD seems to be over-activated
intestinal immune response against luminal antigen(s).
Accordingly, in active IBD, the mucosa is infiltrated with
large numbers of granulocytes, lymphocytes, plasma
cells, and macrophages. These immunocompetent cells
produce cytokines such as TNF-a, IL-1-b, IL-6, IL- 8, IL-
12, IL-23, and IFN-g, which further stimulate the local
inflammation [25-29]. Indeed, histological examinations
of mucosal biopsies from patients with active IBD reveal a
spectrum of pathologic manifestations among which the
abundance of neutrophils relates specifically to clinical
activity and severity of the disease [30]. Since cytokines
from activated granulocytes have a validated role in the
immunopathogenesis of IBD and the fact that circulating
monocytes are recruited for antigen-presenting functions
in the inflammation [26-28,31], these cells appear as logi-
cal targets for down-regulating the inflammation. Granu-
locyte/Monocyte Adsorption (GMA) constitutes an
extracorporeal perfusion of the blood through a column
filled with cellulose acetate beads binding the aforemen-
tioned immune cells to the matrix. The anti-inflamma-
tory effect of GMA is supported by a recently published
meta-analysis [32]. Therefore, it appears interesting to
apply selective granulocyte and monocyte adsorption
(Adacolumn®) to patients with chronically active IBD
refractory to conventional medication.
This open-label, observational study was set out to
investigate efficacy, safety and quality of life in patients
with chronic activity in IBD with focus on re-treatment
strategy with GMA and long-term follow-up.
Methods
Ethical considerations
The Adacolumn is CE marked with regulatory approval
in all countries of the EU territories. All patient data was
d e a l t  w i t h  i n  a n  a n o n y m o u s  w a y .  T h i s  s t u d y  w a s
approved by the regional ethical committee of Stockholm
(Dnr: 2009/367-31/2). Signed informed consent was
obtained from all patients.
Device description
Granulocyte/monocyte apheresis (GMA) with Adacol-
umn® (Otsuka, London, UK) is an extracorporeal device.
The apheresis column (about 20 cm long × 9 cm in diam-
eter poly-carbonate cylinder) contains specially designed
cellulose acetate beads (35 000 beads), each with an aver-
age diameter of 2 mm, in physiological saline buffer [33].
The column has a capacity of 335 ml. Adacolumn® is con-
nected to the patient by two venous blood lines and blood
is circulated through the column with the help of a pump
(Adamonitor). Before start, the system is primed by phys-
iological saline containing an anticoagulant (Heparin,
5000 IE in 1000 ml of physiological saline) and during
extracorporeal circulation Heparin is continually added,
(100IE/ml, 15 ml/hour is used). The apheresis procedure
lasts for 60 minutes and the system forms an extracorpo-
real circuit interposed between two veins, preferentially
in the antecubital fossae using 1,3 mm Venflon® needles.
As blood passes through the column, granulocytes and
monocytes are selectively adsorbed to the beads [24,33].
In contrast, lymphocytes and erythrocytes do not adhere
to the matrix [24,34], and return to the patient via the col-
umn outflow line. This selective adsorption of activated
granulocytes and monocytes is expected to reduce the
inflammatory activity associated with TNF-α, IL-1-b, IL-
6, IL- 8 and IL23 [25-29]. The adsorbed cells are rapidly
replaced by mobilisation of inactive leukocytes, i.e.
CD10− neutrophils and HLA-DR (low) down-regulated
monocytes from the bone marrow [34].
Patients
This observational study was carried out in an open Gas-
troenterology ward at South Hospital in Stockholm, from
April 2002 to December 2006. IBD-patients with chronic
inflammation in spite of conventional medication were
consecutively recruited and prospectively registered. All
40 eligible patients accepted GMA treatment. The ulcer-
ative colitis patients were assessed by the UC disease
activity index UC-DAI [35] and the Crohn's disease
patients were assessed by Harvey Bradshaw Index (HBI)
[36]. Forty patients were treated with GMA therapy: 15
chronically active UC-patients with mean disease activity
index (UC-DAI) of 8,1 (range 4-9) and 25 chronically
active CD-patients with mean HBI of 12,5 (range 5-27).
UC-DAI and HBI were initiated from the second patient.
Chronic activity was defined as at least six months dura-
tion without remission in spite of conventional treatment
in optimal time and dosage (corticosteroids, 5-aminosali-
cylates, azathioprine or 6-mercaptopurine). In addition,
all CD patients were offered infliximab treatment but 16
declined due to concern over side-effects. The patients
received weekly GMA sessions for a period of 5-10 weeks
(mean 8 weeks). Initially five sessions were administratedLindberg et al. BMC Gastroenterology 2010, 10:73
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t o  a l l  p a t i e n t s  f o l l o w e d  b y  e v a l u a t i o n .  I n  c a s e  o f  n o n -
response 1-3 additional sessions were given.
All treatments were provided by two GMA-trained and
experienced IBD nurses. Before GMA, the current vessels
were pre-treated with EMLA® -plaster (local anaesthetic
with lidokain and prilokain) to decrease rupture and
inflammation of the veins. The patients were also
instructed to appear warmly dressed to diminish prob-
lems with venous access and to be well hydrated to avoid
headache during or after treatment. The patients' demo-
graphic characteristics, previous medication, disease
location, smoking status and activity are presented in
Table 1. This cohort of 40 patients represents a sub-group
of patient's refractory to conventional therapy. Notewor-
thy, 36% of the included CD-patients were non-respond-
ers to prior infliximab treatment. Twenty-five patients
were treated with concomitant Azathioprine and 18
patients were medicated with 5-ASA at stable doses
throughout treatment and follow up. Seven patients
achieving remission in this study were given tapering sys-
temic Prednisolone (median dose 17,5 mg, range 5-40
mg) at start of the apheresis treatment. All patients were
free from systemic corticosteroids at end of treatment.
Evaluation
Efficacy assessments were performed after each com-
pleted GMA course and then at week 10 and 20 post-
treatment. Response was classified according to three
categories: 0 = no change or worsening of symptoms; 1 =
partial response: improvement or tapering of steroids
without worsening; 2 = complete remission, absence, or
near absence of all clinical symptoms without an increase
in steroid dose [37]. In addition, endoscopic assessment
(at least flexible sigmoidoscopy) was performed in all
colonic disease (UC and CD) patients according to UC-
DAI. Normal mucosa (mucosal appearance = 0) was clas-
sified as complete remission and erythema and decreased
vascular pattern was classified as response (mucosal
appearance = 1). Patients with mucosal appearance >1
were classified as non-responders. Patients who achieved
remission within 20 weeks were monitored clinically and
endoscopically every third month. HRQoL measurement
by Short Health Scale (SHS) was initiated from the sixth
patient in the study. SHS is a validated four-item self-
administrated disease-specific questionnaire that
includes major health dimensions such as symptom bur-
den, function, disease-related worry and general well-
being. The responses were scored on a 100 mm visual
analogue scale [38,39].
Re-treatment
During follow-up time, all patients were instructed to
inform the study team concerning significant changes in
their disease status. Relapsing patients were re-treated
with GMA.
Statistical analysis
The levels of SHS sub-scales and the scores according to
HBI and UC-DAI are shown in box plots, one box per
time point measured. Boxes show interquartile range at
each time with median presented in bold. Differences in
m e d i a n  s c o r e  b e t w e e n  t i m e  p o i n t s  w e r e  t e s t e d  b y  t h e
Mann-Whitney test, p-values presented in the figure. The
laboratory measurements were tested for differences
between groups by Kruskal-Wallis test (for Haemoglobin,
White cell count and Albumin) and by χ2-test (for C-
reactive protein). Analyses and graphs were performed in
R 2.7.2 and a p-value of 0.05 or less was considered signif-
icant.
The differences in survival curves were tested with log
rank test and were performed in PASW statistics 18.
Results
Clinical efficacy
A total of 453 GMA procedures were performed and ade-
quate venous access was achieved in all patients. Thus, no
patients were excluded due to inadequate venous access.
Out of 40 patients with chronically inflamed mucosa (15
with UC and 25 with CD) and refractory to conventional
medications, 34 (85%) responded to GMA. Furthermore,
26 patients, ten with UC and 16 with CD (65%) achieved
clinical as well as endoscopic remission for an average of
14 months, ranging from two to 58 months (Figure 1).
The laboratory data are summarised in Table 2. HBI- and
UC-DAI-outcome, significant when assessed between
baseline and 20 weeks follow-up, are displayed as box
plots in Figure 2. Data from three patients are missing
(UC-DAI and HBI were initiated from the second patient
and one CD-patient had ileostoma).
Among patients that achieved remission eleven main-
tained azathioprin and ten amonosalicylates throughout
treatment and follow up.
GMA-treatment of relapsed patients
During the follow-up time 14 out of 26 (ten CD and four
UC) patients, who initially achieved clinical and endo-
scopic remission after GMA-treatment, relapsed. These
patients were re-treated with GMA, which resulted in 13
(93%) patients achieving a second remission. Following
further relapses, all of seven patients were successfully re-
treated for the third time, all of three patients for the
fourth time and one patient for a fifth time. Thus, the
remission rates after the first, second, third fourth and
fifth course of GMA treatment were 65%, 93%, 100%,
100% and 100%, respectively (albeit in small groups of
patients). All 26 patients who initially achieved remissionLindberg et al. BMC Gastroenterology 2010, 10:73
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Table 1: Patient characteristics
UC CD
N1 5 2 5
Gender (n)
Female 4 11
Male 11 14
Age median (range) 25 (16-57) 33 (18-51)
Disease duration (y) (median, range) 1-40 (10,7) 1-25 (9,6)
Smokers 0 0
Disease severity (UCDAI, HB) (n)
Mild 1
Moderate 13
Severe
>5 in HB (range) 24 (5-27)
Previous medication (n)
Aminosalicylates 15 25
Glucocorticosteroids 15 25
Immunomodulators (6-MP/AZA) 15 25
Infliximab 9
Antibiotics 12 23
Patients with extraintestinal manifestations (n) 4 12
Patients with previous abdominal surgery for IBD (n) 4 6
Patients with perianal fistulas (n) 5
Disease location
Extensive 6
Left side 7
Proctitis 2
Extensive colonic 21
Small bowel + colonic 1
Esofagus + small bowel 1
Stomach + small bowel + colonic 1
UCDAI score of 3 to 6 is defined as mild, 7 to 10 as moderate and 11 to 12 as severe UC.
HB score ≥ 5 defined as active CDLindberg et al. BMC Gastroenterology 2010, 10:73
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became corticosteroid-free during the follow-up period.
Other concomitant medications at inclusion were stable
throughout follow-up. However, two patients deterio-
rated in their second and fourth re-treatment. One of
these patients went into remission after additional intra-
venous corticosteroids and the other patient reached
remission after infliximab treatment and continued on
that medication. Three patients who achieved remission
were retreated with corticosteroids as rescue therapy for
relapse due to temporary limited access of Adacolumns.
Additional therapy during the GMA treatment and fol-
low-up was limited to these patients.
Proportion of patients achieving remission and propor-
tion of patients staying in remission over time are shown
in Figure 3. Remissions are achieved significantly faster
after the second treatment (p = 0.015).
Quality of life assessment
HRQoL scoring evaluated according to SHS was signifi-
cantly increased in all sub-groups assessed from baseline
to week 20 as presented in Figure 4.
Safety and tolerability
The GMA treatment was well tolerated. No serious side
effects related to GMA were observed. Two patients
developed transient headache, one person severe, and
four patients exhibited transient fatigue. No patients dis-
continued the GMA therapy; thus compliance reached
100% in the investigated.
Discussion
Studies of immunopathogenesis behind IBD have
recently identified the innate immune system as a major
player in mucosal inflammation [40]. The activated gran-
ulocytes and macrophages are important sources of pro-
inflammatory cytokines [21,25,31]. Moreover, some of
the pro-inflammatory monocytes are known to develop
into locally infiltrating dendritic cells, which are profes-
sional antigen-presenting cells that maintain the mucosal
inflammation by continuous stimulation of naïve T cells
[41,42]. In this context, the removal of these cells by leu-
kocytapheresis provides us with a treatment strategy that
targets major catalysts behind the intestinal inflamma-
tion. Furthermore, GMA (Adacolumn®) has been shown
to improve clinical symptoms in patients with UC
[22,24,43] and CD [44,45]. GMA treatment has also been
suggested to significantly reduce the dosage of predniso-
lone required to relieve symptoms in active UC-patients
[46]. A pilot study by Bresci et al even implies that GMA
is more effective with less frequent and serious side
effects than prednisolone in acute UC [47]. Maiden and
co-workers recently confirmed the efficacy of Adacolumn
apheresis treatment in reducing relapse rates in UC as
well as CD patients [48]. However, to our knowledge the
present study is the first to elucidate the effect of GMA-
treatment in long-term follow-up including re-treatment
at relapse.
The consecutive recruitment of patients with chronic
inflammation resulted in a UC/CD ratio of 3/5 which
Table 2: Laboratory data
Before treatment 10 weeks after treatment 20 weeks after treatment
Remission patients (n = 26)
Haemoglobin Mean g/l (range g/l) 135 (97-164) 134 (95-154) 137 (117-162)
Mean white cell count x10/1 (range) 7.8 (1.8-15.6) 7.1 (2.4-15.8) 6.8 (0.0-12.6)
Albumin Mean g/l (range g/l) 39.4 (33.0-50.0) 39.8 (34.0-45.0) 40.3 (31.0-48.0)
CRP N 10 mg/l or over (total) 3 (23) 3 (23) 2 (22)
Responded patients (n = 8)
Haemoglobin Mean g/l (range g/l) 135 (100-162) 127 (107-156) 130 (113-150)
Mean white cell count x10/1 (range) 12.5 (9.7-17.2) 8.9 (6.0-11.3) 8.6 (3.8-10.8)
Albumin Mean g/l (range g/l) 34.8 (29.0-41.0) 37.6 (33.0-42.0) 36.7 (32.0-39.0)
CRP N 10 mg/l or over (total) 3 (8) 2 (7) 3 (7)
Non response patients (n = 6)
Haemoglobin Mean g/l (range g/l) 120 (82-164) 122 (93-146) 131 (112-153)
Mean white cell count x10/1 (range) 8.9 (4.8-24.3) 8.3 (5.4-19.7) 10.5 (4.6-21.6)
Albumin Mean g/l (range g/l) 39.0 (35.0-42.0) 37.3 (32.0-41.0) 37.5 (34.0-41.0)
CRP N 10 mg/l or over (total) 3 (6) 2 (6) 3 (5)
Before treatment only white cell count differed significantly (p = 0.004) between the three groups (remission/response/non-responders). At 
20 weeks after treatment, however, as white cell count still differed significantly between the groups (p = 0.038), so did Albumin (p = 0.038) 
and C-Reactive Protein (p = 0.021).Lindberg et al. BMC Gastroenterology 2010, 10:73
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Figure 1 Individual IBD patients with chronic active disease refractory to conventional medications. Patients in clinical and endoscopic remis-
sion secondary to selective apheresis treatment. Follow-up time in months.
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Figure 2 Scores on Harvey Bradshaw Index (HB) and Ulcerative Colitis Disease Activity Index (UCDAI) in boxplots. Boxes show interquartile 
range at each time. Median in bold. Differences in median score between time points were tested by the Mann-Whitney test, p-values presented. P-
value ≤ 0,05 was considered significant HB score >5 is defined as active disease. UCDAI score of 3 to 6 is defined as mild, 7 to 10 as moderate and 11 
to 12 as severe disease
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may reflect the prevalence [18,19]. The relatively small
proportion of CD patients with small bowel involvement
in this study, 3/25 (12%) compared to expected 48% in
Stockholm County [49], may indicate a higher risk for CD
patients with colonic inflammation to become chronic.
However this reflection remains speculative within the
scope of this report. An explanation to this recruitment
discrepancy might also be a preference to refer patients
with chronic inflammation localized to the small bowel
or ileo-caecal region to limited surgery while trying GMA
treatment on the colitis patients before colectomy.
This study includes a cohort of refractory patients who
were re-treated with GMA upon relapse. We found that
close to 100% of the patients who initially responded to a
course of GMA also responded to subsequent GMA re-
treatments. This may serve as a guide to select respond-
ers in the light of the high cost of this treatment.
In the present study including, 40 patients with chroni-
cally active IBD (15 with UC and 25 with CD) refractory
to conventional medications, 34 patients (85%)
responded to GMA. Further, 26 patients (65%) remained
in clinical as well as endoscopic remission for an average
of 14 months, ranging from two to 58 months. These
remission values (65%) are in line with other studies,
however with more homogenous patient selection
[45,50]. All 26 patients remained steroid-free during the
follow-up period. Hence, GMA implicated substantial
steroid-sparing effects. During the follow-up time,
patients with relapsed disease were re-treated with GMA,
resulting in high remission rates after the second to
fourth time of GMA treatment. This finding indicated
that maintenance therapy would be an interesting option
but in lack of evidence at that time such a regime was not
regarded as appropriate. Evidence for maintenance ther-
apy has however recently been shown [48].
These encouraging results must be critically judged in
the light of the open uncontrolled study design. Extracor-
poreal treatment may hold substantial placebo effects,
even more pronounced than seen in similar patients
groups [51]. However, the patients included in this study
were chronically inflamed and refractory to prior conven-
tional treatments and almost all first-time responders
who relapsed during the study period reached remission
following re-treatment. The expected remission rate in
one year in this sub-group of patients is unknown. The
65% clinical and endoscopic remission rate noted in the
present group is in contrast to the placebo-controlled and
randomised study [52] which was unsuccessful in reach-
ing significant treatment effect. However, the placebo-
controlled study included a more heterogeneous group of
IBD-patients regarding disease patterns. In addition, the
follow-up time only reached two to three weeks after
completed GMA course. The discrepancy between the
outcome of the current study and the aforementioned
placebo-controlled study might possibly be explained by
the presumption that chronically inflamed patients repre-
sent a more homogenous immunological phenotype
regarding the importance of monocytes for driving the
inflammation.
A total of 453 GMA procedures were performed and
adequate venous access was achieved in all patients.
Therefore, no exclusion of patients due to inadequate
venous access was reported. Unlike other studies [53], we
could overcome the problems with venous access partly
by ensuring good peripheral blood flow and partly by
using non-traumatising needles. The GMA treatment
was well tolerated without serious side effect related to
the apheresis procedure. Two patients developed tran-
sient headache, one person severe, and four patients
showed transient fatigue. No patient discontinued the
GMA treatment, which resulted in a compliance of 100%.
Figure 3 Proportion of patients achieving remission and propor-
tion of patients staying in remission over time.Lindberg et al. BMC Gastroenterology 2010, 10:73
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HQoL were significantly increased in all sub-groups
assessed between baseline and week 20. This is promising
since the consistent active patients seem to reach lower
quality of life scoring compared to other sub-groups [20].
However, the dimensions "worry" and to a lesser extent
even "general well being" in SHS increased assessed
between the later time points measured. The impending
fact that the close caring and weekly monitoring of these
patients was reaching a final stage could partly explain
these findings, in spite of the good contact availableness
to the IBD nurses in continuation.
A total of 323 GMA sessions were given to the remis-
sion patients upon relapse and a total of 566 months in
remission was achieved, equivalent to 1.75 months per
apheresis column for patients in remission, which reflects
a cost of 1150 $/remission month.
All 40 patients in the study suffered from chronic
inflammation, defined as at least six months without
remission in spite of conventional medication including
immunosuppressors. Taking the pre-treatment clinical
activity into account, each patient may be regarded as her
or his own control. The continuous time period with
active IBD prior to entry does not suggest that the GMA-
induced remission correlates with the natural course of
the disease in these chronically debilitated patients.
Nonetheless, the observations in this relatively small
cohort of IBD patients need to be further investigated in
prospective, randomised controlled trials including larger
cohorts of IBD-patients.
A sub-group of patients with IBD is characterised by a
chronically activated immune response with a persis-
tently inflamed mucosa. Defects in the innate immune
response may be a major contributor to the onset of the
inflammation, reflected by continuous activation of gran-
ulocytes and monocytes [40]. These cells are crucial
sources for the pro-inflammatory cytokines seen in the
intestinal lesions [31], and many of the circulating mono-
cytes are targeted for antigen-presenting functions at the
inflammatory site[31]. Hence, the removal of these leuko-
cytes by extracorporeal selective adsorption may be an
Figure 4 The levels of subscales of the Short Health Scale (SHS) in boxplots , one box per time point measured. Boxes show interquartile range 
at each time, median in bold. Differences in median score between time points were tested by the Mann-Whitney test. P-value ≤ 0,05 was considered 
significant.
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efficient approach to down-regulate the immune
response in patients with limited effects from conven-
tional medication.
Conclusions
85% of the drug-refractory patients responded to GMA.
The remission rate among relapsing patients was close to
100%. Technical feasibility and patient's tolerability were
excellent. These finding may indicate that scheduled
therapy with GMA should be evaluated in IBD patients
with chronic disease activity who respond to an initial
GMA course.
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